hy-n6707 Search Results


triacsin c  (MedChemExpress)
94
MedChemExpress triacsin c
Targeting ACSL5 and FAO reverses SS symptoms in vivo . (A) Correlations of ACSL5 expression with disease stage ( GSE23117 ). (B) Schematic of the adoptive transfer of CD4 + T cells, followed by ESS induction and in vivo evaluation of disease severity and T-cell phenotypes. (C) H&E staining of representative salivary glands and quantification of histological scores and lymphocyte foci (scale bar = 50-500 μm). The black boxes indicate lymphocytic foci. (D) Serum SSA and SSB levels in the indicated groups. (E) CD4 + T-cell and T-cell subpopulation ratios in the spleens of the indicated groups. (F) CD4 + T-cell and T-cell subpopulation ratios in the lymph nodes of the indicated groups. (G) CD4 + T-cell and T-cell subpopulation ratios in the submandibular salivary glands of the indicated groups. (H) Representative plots of CD4 + T cells in the spleen and lymph nodes of the indicated groups. (I) Representative plots of T-cell subpopulations in the spleen, lymph nodes, and submandibular salivary glands of the indicated groups. (J) H&E staining of representative salivary glands and quantification of disease severity (scale bar = 100-1000 μm). (K) Flow cytometry of T-cell subpopulations in Triacsin C/etomoxir-treated vs. control mice at 12 weeks of age. The data are presented as the means ± SDs. n = 15 biological replicates for panel A, and n = 5 biological replicates for panels C-K. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical analyses were performed using two-tailed tests, two-way ANOVA, and one-way ANOVA.
Triacsin C, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n6707/Triacsin+C/pmc13411838-79-27-31
Average 94 stars, based on 1 article reviews
triacsin c - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Targeting ACSL5 and FAO reverses SS symptoms in vivo . (A) Correlations of ACSL5 expression with disease stage ( GSE23117 ). (B) Schematic of the adoptive transfer of CD4 + T cells, followed by ESS induction and in vivo evaluation of disease severity and T-cell phenotypes. (C) H&E staining of representative salivary glands and quantification of histological scores and lymphocyte foci (scale bar = 50-500 μm). The black boxes indicate lymphocytic foci. (D) Serum SSA and SSB levels in the indicated groups. (E) CD4 + T-cell and T-cell subpopulation ratios in the spleens of the indicated groups. (F) CD4 + T-cell and T-cell subpopulation ratios in the lymph nodes of the indicated groups. (G) CD4 + T-cell and T-cell subpopulation ratios in the submandibular salivary glands of the indicated groups. (H) Representative plots of CD4 + T cells in the spleen and lymph nodes of the indicated groups. (I) Representative plots of T-cell subpopulations in the spleen, lymph nodes, and submandibular salivary glands of the indicated groups. (J) H&E staining of representative salivary glands and quantification of disease severity (scale bar = 100-1000 μm). (K) Flow cytometry of T-cell subpopulations in Triacsin C/etomoxir-treated vs. control mice at 12 weeks of age. The data are presented as the means ± SDs. n = 15 biological replicates for panel A, and n = 5 biological replicates for panels C-K. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical analyses were performed using two-tailed tests, two-way ANOVA, and one-way ANOVA.

Journal: International Journal of Biological Sciences

Article Title: ACSL5 programs fatty acid metabolism and mitochondrial fitness to sustain pathogenic T cells and exacerbate Sjögren's syndrome

doi: 10.7150/ijbs.131033

Figure Lengend Snippet: Targeting ACSL5 and FAO reverses SS symptoms in vivo . (A) Correlations of ACSL5 expression with disease stage ( GSE23117 ). (B) Schematic of the adoptive transfer of CD4 + T cells, followed by ESS induction and in vivo evaluation of disease severity and T-cell phenotypes. (C) H&E staining of representative salivary glands and quantification of histological scores and lymphocyte foci (scale bar = 50-500 μm). The black boxes indicate lymphocytic foci. (D) Serum SSA and SSB levels in the indicated groups. (E) CD4 + T-cell and T-cell subpopulation ratios in the spleens of the indicated groups. (F) CD4 + T-cell and T-cell subpopulation ratios in the lymph nodes of the indicated groups. (G) CD4 + T-cell and T-cell subpopulation ratios in the submandibular salivary glands of the indicated groups. (H) Representative plots of CD4 + T cells in the spleen and lymph nodes of the indicated groups. (I) Representative plots of T-cell subpopulations in the spleen, lymph nodes, and submandibular salivary glands of the indicated groups. (J) H&E staining of representative salivary glands and quantification of disease severity (scale bar = 100-1000 μm). (K) Flow cytometry of T-cell subpopulations in Triacsin C/etomoxir-treated vs. control mice at 12 weeks of age. The data are presented as the means ± SDs. n = 15 biological replicates for panel A, and n = 5 biological replicates for panels C-K. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical analyses were performed using two-tailed tests, two-way ANOVA, and one-way ANOVA.

Article Snippet: Female NOD/Ltj mice (8 weeks old; GemPharmatech, Nanjing, China) under specific pathogen-free (SPF) conditions received intraperitoneal injections of etomoxir (15 mg/kg; Selleck, Houston, TX, USA; Cat# S8244), Triacsin C (15 mg/kg; MedChemExpress, Monmouth Junction, NJ, USA; Cat# HY-N6707), or the solvent control twice weekly for one month.

Techniques: In Vivo, Expressing, Adoptive Transfer Assay, Staining, Flow Cytometry, Control, Two Tailed Test